Tandem Health Expands Europe, Rejects Dependence on OpenAI

According to Sifted, Swedish medical scribe startup Tandem Health reported rapid expansion in 2025. CEO Lukas Saari is quoted by Sifted saying, "In 2025 we grew more than tenfold." Sifted reports Tandem increased the number of healthcare providers using its tool from just above 1,000 to 5,000 since June last year and that the service is operational across 12 European countries, with the UK as its largest market. Tech.eu reports Saari and the CEO of another Swedish AI startup publicly rejected the idea that well-funded frontier labs such as OpenAI and Anthropic pose a threat to their business models.

Tandem Health is described in coverage as a medical scribe or medical copilot product built for clinicians; this is a low-level description of the product category reported by Sifted. Tech.eu notes recent vertical moves from frontier model providers, including ChatGPT Health (an OpenAI feature launched in the US) and an Anthropic legal plug-in, as recent examples of larger labs developing domain-focused tooling.

Editorial analysis: Companies offering vertical, domain-specific AI tools have seen demand increase when mainstream consumer-facing models raise awareness. Observers following the space note that releases like ChatGPT Health or specialized plug-ins by Anthropic often act as a market signal that generates enterprise interest, while leaving room for startups that assemble domain data, integrations, and workflows on top of model outputs.

Editorial analysis: Tandem's reported growth to 5,000 providers and multi-country operations place it in the cohort of European healthtech startups scaling product-market fit. Coverage framing by Tech.eu highlights a broader sector conversation: well-funded model providers are delivering vertical features, but founders at local startups characterise those moves as demand catalysts rather than direct displacement. For practitioners, the distinction matters because competing solutions differ along integration, data governance, and regulatory compliance axes.

Editorial analysis: Observers should track three indicators: published adoption metrics or customer case studies from Tandem and peers; product integrations with EHR vendors and compliance certifications in major markets; and product announcements or vertical feature rollouts from frontier providers that target regulated health data. Changes on any of these axes would materially affect enterprise adoption dynamics in clinical settings.